Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis.
about
PACSIN 2 represses cellular migration through direct association with cyclin D1 but not its alternate splice form cyclin D1bThe systemic cytokine environment is permanently altered in multiple myelomaIL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion.Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo.Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4Epithelial interleukin-4 receptor expression promotes colon tumor growth.Interleukin-4 and interleukin-13 increase NADPH oxidase 1-related proliferation of human colon cancer cells.Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.Polysaccharide from Lentinus edodes inhibits the immunosuppressive function of myeloid-derived suppressor cells.Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions.Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease.Expression of IL-4 and IL-13 predicts recurrence and survival in localized clear-cell renal cell carcinoma.IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation.Gene set enrichment analysis identifies LIF as a negative regulator of human Th2 cell differentiationTNF signaling drives myeloid-derived suppressor cell accumulation.Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer.Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case-control epidemiological observationsTH9 cells in anti-tumor immunity.Autoimmunity as a double agent in tumor killing and cancer promotion.Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13.IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model.Poor antibody validation is a challenge in biomedical research: a case study for detection of c-FLIP.Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages.Tissue-derived hedgehog proteins modulate Th differentiation and disease.TNFR-1 on tumor cells contributes to the sensitivity of fibrosarcoma to chemotherapy.Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.Clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer.Hyperglycemia of tumor microenvironment modulates stage-dependent tumor progression and multidrug resistance: implication of cell survival regulatory molecules and altered glucose transport.Early exposure of high-dose interleukin-4 to tumor stroma reverses myeloid cell-mediated T-cell suppression.Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer.
P2860
Q24610494-7D7707D6-8277-473A-B3B7-F6FF5361C8D8Q28489028-CC98DF79-D269-41E1-99E1-919E83246E2BQ33612349-53177FDB-7F1F-4E17-A348-570B9BC730D0Q33624331-2E40030B-032B-43FE-B957-0F647E844149Q33680523-D37DDB9B-6863-4881-90AF-20C429B92060Q33884582-8904EBDC-17F6-402F-BA99-11D1338EC5D7Q33888701-856E7AF6-3549-4C9D-BFAF-BD62BFE61A66Q34055865-AC5950B3-EE39-412B-B7D3-4A3138E9F46FQ34525608-06DA33EF-4BF8-4B83-B621-ED9E21CF35DDQ34619781-49B5F603-C74B-401B-9B2A-D3F0F4378C25Q34982602-42BD7632-CBA2-431E-8A35-FC21541F81E6Q35405080-0BB975B3-0D84-48FE-A9E1-4CD6C34C82CCQ35914656-57570AF9-E7BF-4263-BC52-4B31CB449746Q36036457-494F95EE-4C0B-4557-9FE0-A63DA7BE06C7Q36357903-24376B3D-61F2-455B-B10D-1FF78DAC95A3Q36838928-D73A33F3-1EA4-482D-A5CA-1970C2F40189Q37205878-47819EE4-0CB9-467C-9B32-23ADFF5428AAQ37575177-C4270C1A-D96A-47E4-8DFC-0A2CE99492A8Q37642271-309C840F-54F8-4F39-BD90-1BC3EB03F090Q38065873-9032C850-9612-4CDF-AE53-F41E4D79DE5EQ38667135-2831E9DF-C612-4090-9960-3FA1DCD2C3C1Q39114961-22C2A520-AD2C-4046-9F47-F24A9391CD85Q39409408-7C497455-C01C-4F55-8A35-CC700828F3E0Q41546088-19AA3AC0-D8A5-49CF-9681-E33FB878407FQ42086523-1CE6F3EC-D94F-44FB-B795-8EE8809E21F5Q42128311-DD4D0FFC-FD9B-473A-8A68-E4B39CBD58EEQ42585544-B2157FD9-6375-4F51-B459-2098A1548252Q43520655-82EAC5BB-6E16-4139-9609-C03A1A7CFFABQ45858579-88DA4374-202F-4317-9696-F1A0592A4BC1Q50893711-79B6F7C2-AF54-43F7-BEDE-6251D29B7F2B
P2860
Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Endogenous interleukin-4 promo ...... cell resistance to apoptosis.
@en
Endogenous interleukin-4 promo ...... cell resistance to apoptosis.
@nl
type
label
Endogenous interleukin-4 promo ...... cell resistance to apoptosis.
@en
Endogenous interleukin-4 promo ...... cell resistance to apoptosis.
@nl
prefLabel
Endogenous interleukin-4 promo ...... cell resistance to apoptosis.
@en
Endogenous interleukin-4 promo ...... cell resistance to apoptosis.
@nl
P2093
P1433
P1476
Endogenous interleukin-4 promo ...... cell resistance to apoptosis.
@en
P2093
Chunhui Wang
Jing Jiang
Jinhua Zhang
Mingjie Xiao
Zhiguang Li
Zhihai Qin
Zibing Wang
P304
P356
10.1158/0008-5472.CAN-08-0449
P407
P577
2008-11-01T00:00:00Z